- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04949568
Self-Management and Glycemic Control in Adult Haitian Immigrants With Type 2 Diabetes
July 21, 2025 updated by: New York University
Self-Management and Glycemic Control in Adult Haitian Immigrants With Type 2 Diabetes: A Pilot Randomized Study
The objective of the study is to conduct a pilot randomized study to test feasibility and preliminary efficacy of the developed diabetes self-management education program with 40 adult Haitian immigrants.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This is a two-arm randomized trial.
Participants will be randomized to the culturally tailored Diabetes Self-Management Education Program or standard care condition in a 1:1 allocation.
All participants will receive standard type 2 diabetes care at the enrolled clinic and remain under their providers' care for the duration of the study.
The culturally tailored Diabetes Education Program involves the following: 1) an initial 45-minute face-to-face consultation; and 2) six 2-hour weekly interactive educational sessions in a format to be determined (TBD) by Aim 1 (e.g., in-person, video/telephone conference call).
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10010
- New York University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Self-described Haitian immigrant aged 21 and older
- Known diagnosis of type 2 diabetes for at least one year
- Have lived in the US for at least one year
- Have an HbA1c of 7.5%
- Willing and able to participate in an individual interview
Exclusion Criteria:
- Having a diagnosis of type 1 diabetes
- Unable to comprehend, consent and or fully participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Diabetes Self-Management Behaviors
Self-Management Education Program The culturally tailored Diabetes Self-Management Education Program involves the following: 1) an initial 45-minute face-to-face private consultation collaboratively determining goals; followed by 2) six 2-hour weekly educational interactive sessions in a format TBD by aim 1.
We will deliver culturally targeted written materials and presentations in these sessions.
Participants will be asked to practice self-management behaviors concurrently and for four additional weeks.
|
The intervention is to be delivered by an interventionist.
|
|
No Intervention: Usual Type 2 Diabetes Care
The usual care arm will receive the clinic's standard type 2 diabetes care and remain under their providers' care for the duration of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Summary of Diabetes of Self-Care Activities Scale (11- item)
Time Frame: (T0) baseline through (T3) 90 days post-intervention
|
Change in diabetes self-management behaviors (0-7, higher scores indicate improvement)
|
(T0) baseline through (T3) 90 days post-intervention
|
|
Stanford Diabetes Self-Efficacy Scale (8- item)
Time Frame: (T0) baseline through (T3) 90 days post-intervention
|
Change in general self-efficacy 1-10, higher scores indicate improvement)
|
(T0) baseline through (T3) 90 days post-intervention
|
|
Wrist-worn actigraphy (ActiGraph) to be worn while awake
Time Frame: (T0) baseline through (T3) 90 days post-intervention
|
Change in physical activity (Frequent physical activity indicates improvement)
|
(T0) baseline through (T3) 90 days post-intervention
|
|
Glucose Variability data from continuous glucose monitor (CGM) will be downloaded directly from participants provided (blinded) FreeStyle Libre Pro
Time Frame: (T0) baseline through (T3) 90 days post-intervention
|
Time in range and glucose variability (More time in range and less glucose variability indicates improvement)
|
(T0) baseline through (T3) 90 days post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diabetes Distress Scale (DDS) (17-item), using Numerical Rating Scale: 0-6
Time Frame: (T0) baseline through (T3) 90 days post-intervention
|
Change in diabetes distress ( 0-6, lower scores indicates improvement)
|
(T0) baseline through (T3) 90 days post-intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Cherlie Magny-Normilus, PhD, FNP-BC, FAAN, New York University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 12, 2023
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
June 25, 2021
First Submitted That Met QC Criteria
July 1, 2021
First Posted (Actual)
July 2, 2021
Study Record Updates
Last Update Posted (Actual)
July 22, 2025
Last Update Submitted That Met QC Criteria
July 21, 2025
Last Verified
October 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-9103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
Clinical Trials on Diabetes Self-Management Behaviors
-
OsakidetzaFondo de Investigacion Sanitaria; Kronikgune-- Association Centre of International... and other collaboratorsCompleted
-
University of MichiganActive, not recruiting
-
University of MichiganNational Institutes of Health (NIH); National Institute on Aging (NIA); Blue...Completed
-
University of ArkansasPatient-Centered Outcomes Research InstituteCompletedDiabetes Mellitus, Type 2United States
-
US Department of Veterans AffairsCompletedDiabetes Mellitus Self Management Education | Hyperglycemic Control | High Risk DiabetesUnited States
-
American Association of Diabetes EducatorsBristol-Myers SquibbUnknownDiabetes Mellitus Type 2United States
-
National Institute of Diabetes and Digestive and...CompletedDiabetes Mellitus, Non-Insulin-DependentUnited States
-
Universiti Putra MalaysiaNot yet recruitingDiabetes Mellitus Type 2Pakistan
-
Emory UniversityGeorgia Center for Diabetes Translation ResearchCompleted
-
University of NottinghamCompletedDiabetes Mellitus, Type 2 | Health BehaviorJordan